PBYI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Puma Biotechnology Inc (PBYI) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company's financial performance is declining significantly, hedge funds and insiders are selling heavily, and there are no positive catalysts or strong trading signals to support a bullish outlook. Additionally, technical indicators and options sentiment do not suggest a favorable entry point.
The MACD histogram is negative (-0.0394) and contracting, indicating bearish momentum. RSI is neutral at 53.794, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near a key pivot level (6.808), with resistance at 7.158 and support at 6.459. The stock has a 60% chance to decline -2.27% in the next day and -7.03% in the next week.
No positive catalysts identified. Gross margin increased to 77.65%, up 21.58% YoY, which is a minor positive.
Hedge funds and insiders are selling heavily, with hedge fund selling up 203.10% last quarter and insider selling up 230.93% last month. Revenue, net income, and EPS have all dropped significantly YoY in the latest quarter. No recent news or congress trading data to indicate positive sentiment.
In Q3 2025, revenue dropped -32.36% YoY to $54.48M, net income dropped -56.47% YoY to $8.84M, and EPS dropped -58.54% YoY to 0.17. Gross margin increased to 77.65%, up 21.58% YoY, but this is overshadowed by the overall poor financial performance.
No recent analyst rating or price target changes available. Wall Street sentiment appears negative given the lack of positive updates and declining financials.
